Monte Rosa Therapeutics

OverviewSuggest Edit

Monte Rosa Therapeutics is a biopharmaceutical company that develops cancer therapeutics intended to modulate protein degradation pathways. Its technology treats cancer cells through small-molecule drugs that reprogram ubiquitin ligases to eliminate disease drivers.

TypePublic
Founded2018
HQBoston, MA, US
Websitemonterosatx.com

Latest Updates

Employees (est.) (Jun 2021)75
Share Price (Sept 2021)$30.7(-7%)
Cybersecurity ratingAMore

Key People/Management at Monte Rosa Therapeutics

Markus Warmuth

Markus Warmuth

Chief Executive Officer
Ajim Tamboli

Ajim Tamboli

Chief Financial Officer
Sharon Townson

Sharon Townson

Chief Technology Officer
Owen Wallace

Owen Wallace

Chief Scientific Officer
John Castle

John Castle

Chief Data Scientist
Filip Janku

Filip Janku

Chief Medical Officer
Show more

Monte Rosa Therapeutics Office Locations

Monte Rosa Therapeutics has offices in Boston and Basel
Boston, MA, US (HQ)
645 Summer St
Basel, CH
Hochbergerstrasse 60C
Show all (2)

Monte Rosa Therapeutics Financials and Metrics

Monte Rosa Therapeutics Revenue

Market capitalization (17-Sept-2021)

1.4b

Closing stock price (17-Sept-2021)

30.7
Monte Rosa Therapeutics's current market capitalization is $1.4 b.
Show all financial metrics

Monte Rosa Therapeutics Cybersecurity Score

Cybersecurity ratingPremium dataset

A

97/100

SecurityScorecard logo

Monte Rosa Therapeutics Online and Social Media Presence

Embed Graph

Monte Rosa Therapeutics News and Updates

Monte Rosa Therapeutics Announces Addition to Russell 2000® and Russell 3000® Indexes

BOSTON, Sept. 10, 2021 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE), a biotechnology company developing novel molecular glue precision medicines, today announced that it will be added to the Russell 2000® and Russell 3000® Indexes as part of second quarter initial public offeri…

Monte Rosa Therapeutics to Participate in Morgan Stanley 19th Annual Global Healthcare Conference

BOSTON, Sept. 08, 2021 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE), a biotechnology company developing novel molecular glue precision medicines, today announced that Markus Warmuth, M.D., Chief Executive Officer, and Ajim Tamboli, CFA, Chief Financial Officer, are scheduled to…

Monte Rosa Therapeutics Reports Second Quarter 2021 Financial Results and Highlights Pipeline and Business Progress

– Completed upsized $255.6 million IPO; cash runway extended into late 2024

Monte Rosa Therapeutics Announces Pricing of Initial Public Offering

BOSTON, June 23, 2021 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE), a biotechnology company developing a portfolio of novel small molecule precision medicines that employ the body’s natural mechanisms to selectively degrade therapeutically relevant proteins, today announced the…

Monte Rosa Therapeutics Raises $32.5M Financing

Monte Rosa Therapeutics, a Boston, MA-based biotechnology company developing small molecules to degrade disease-related proteins, exited stealth mode with a $32.5m Series A funding. Backers included Versant Ventures and New Enterprise Associates.

Monte Rosa Therapeutics Frequently Asked Questions

  • When was Monte Rosa Therapeutics founded?

    Monte Rosa Therapeutics was founded in 2018.

  • Who are Monte Rosa Therapeutics key executives?

    Monte Rosa Therapeutics's key executives are Markus Warmuth, Ajim Tamboli and Sharon Townson.

  • How many employees does Monte Rosa Therapeutics have?

    Monte Rosa Therapeutics has 75 employees.

  • Who are Monte Rosa Therapeutics competitors?

    Competitors of Monte Rosa Therapeutics include DNAtriX, Autonomous Therapeutics and Lyell.

  • Where is Monte Rosa Therapeutics headquarters?

    Monte Rosa Therapeutics headquarters is located at 645 Summer St, Boston.

  • Where are Monte Rosa Therapeutics offices?

    Monte Rosa Therapeutics has offices in Boston and Basel.

  • How many offices does Monte Rosa Therapeutics have?

    Monte Rosa Therapeutics has 2 offices.